ArticleExperimental and therapeutic medicine2025
Successful surgical management of a patient with osteoradionecrosis of the jaw with RET fusion-positive advanced thyroid cancer: A case report.
Article in Experimental and therapeutic medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoradionecrosis (ORN) of the jaw is a severe complication of radiotherapy for head and neck cancer. Extensive surgical resection has shown promising outcomes; however, patients' prognosis must be considered. Papillary thyroid carcinoma (PTC) generally has a favorable prognosis, whereas metastatic PTC is considered a refractory disease against conventional treatment. Recently, comprehensive genomic profiling (CGP) has enabled clinicians to provide personalized medicine, offering patients with intractable disease further therapeutic options. The present case study reported on a patient with advanced PTC who developed ORN during lenvatinib treatment; extensive surgical treatment with submandibular dissection for ORN provided a favorable outcome. Pathological examination unexpectedly revealed PTC metastases in the dissected right submandibular gland. Postoperatively, the patient experienced worsening metastases to the lung and liver. CGP identified a CCDC6-RET fusion, prompting selpercatinib treatment, which achieved a partial response. This report aims to emphasize that extensive surgical treatment for ORN should be considered, even in patients with advanced cancer, if the patients' condition is stable. In addition, submandibular dissection is warranted in selected patients, particularly when thyroid cancer exhibits an aggressive phenotype with occult metastases. Furthermore, this report highlights the importance of integrating personalized medicine in the management of advanced cancer cases and emphasizes the availability of genomic profiling to guide treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.